FibroBiologics (NASDAQ:FBLG) Earns “Buy” Rating from D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $16.00 price target on the stock.

Several other equities research analysts have also recently weighed in on FBLG. Rodman & Renshaw initiated coverage on FibroBiologics in a research note on Thursday, December 12th. They issued a “buy” rating and a $12.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of FibroBiologics in a research report on Tuesday, April 1st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Trading Down 4.4 %

Shares of NASDAQ FBLG opened at $0.81 on Wednesday. The firm has a fifty day simple moving average of $1.14 and a two-hundred day simple moving average of $2.01. FibroBiologics has a 12 month low of $0.76 and a 12 month high of $13.59. The firm has a market capitalization of $30.67 million, a PE ratio of -2.39 and a beta of 0.16.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. On average, sell-side analysts predict that FibroBiologics will post -0.53 earnings per share for the current year.

Institutional Investors Weigh In On FibroBiologics

Several hedge funds have recently added to or reduced their stakes in FBLG. Geode Capital Management LLC raised its position in shares of FibroBiologics by 90.0% in the 3rd quarter. Geode Capital Management LLC now owns 599,760 shares of the company’s stock worth $1,854,000 after purchasing an additional 284,047 shares during the last quarter. State Street Corp raised its holdings in FibroBiologics by 26.5% in the third quarter. State Street Corp now owns 475,837 shares of the company’s stock worth $1,470,000 after buying an additional 99,789 shares during the last quarter. Jane Street Group LLC raised its holdings in FibroBiologics by 415.3% in the fourth quarter. Jane Street Group LLC now owns 61,074 shares of the company’s stock worth $122,000 after buying an additional 49,222 shares during the last quarter. O Shaughnessy Asset Management LLC bought a new position in shares of FibroBiologics in the fourth quarter worth approximately $81,000. Finally, Barclays PLC grew its holdings in shares of FibroBiologics by 363.2% during the third quarter. Barclays PLC now owns 39,958 shares of the company’s stock valued at $123,000 after buying an additional 31,331 shares during the last quarter.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.